Department of Pharmaco-Biochemistry, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Surugaku, Shizuoka City, Shizuoka 422-8526, Japan.
Nutr Metab (Lond). 2012 Mar 27;9(1):23. doi: 10.1186/1743-7075-9-23.
Rats fed a high-fat and high-sucrose (HF) diet develop hepatic steatosis and hyperlipidemia. There are several reports that a change in nutritional status affects hepatic levels of drug-metabolizing enzymes. Synthetic inulin is a dietary component that completely evades glucide digestion. Supplementing a HF diet with inulin ameliorates hypertriglycemia and hepatic steatosis, but not hypercholesterolemia. This study aimed at distinguishing the effects of synthetic inulin and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin), which inhibit cholesterol biosynthesis.
We examined effects of co-treatment with synthetic inulin (5%) and fluvastatin (0, 4, and 8 mg/kg, per os) on body weight, epidydimal white adipose tissue weight, serum and hepatic lipid profiles, and hepatic cytochrome P450 (CYP) mRNA and protein profiles in rats fed a standard diet or a HF diet for 3 weeks.
Treatment with the synthetic inulin (5%) or fluvastatin at 4 mg/kg (lethal dose in rats fed the HF diet, 8 mg/kg) ameliorated the elevation in hepatic triacylglycerol and total cholesterol levels in rats fed the HF diet. Whereas co-treatment with the inulin (5%) and fluvastatin (4 mg/kg) had a tendency to more strongly suppress the elevation in serum levels of very low density lipoprotein triacylglycerol than either treatment alone, no additive or synergistic effect was found in decrease in hepatic lipid levels. Hepatic levels of CYP1A1/2 and CYP2E1 mRNA and protein and methoxyresorufin O-demethylase and ethoxyresorufin O-deethylase activities were reduced in rats fed the HF diet. The synthetic inulin alleviated the reduction in hepatic levels of CYP1A1/2 and CYP2E1 mRNA and protein more strongly than fluvastatin, and no synergistic effects were observed on co-treatment. Furthermore, hepatic levels of aryl hydrocarbon receptor mRNA were decreased in rats fed the HF diet and recovered to near normal values with the intake of dietary inulin, which correlated with change in CYP1A1/2.
Dietary inulin alone was effective to prevent the development of hepatic steatosis, ameliorate nutritional effects, and alleviate the hepatic change in the expression of CYP1A1/2 and CYP2E1, while co-treatment with statin did not have additive or synergistic effects and statin may cause adverse effects in rats fed the HF diet.
高脂高糖(HF)饮食喂养的大鼠会发生肝脂肪变性和高血脂症。有几项报道称,营养状况的改变会影响肝内药物代谢酶的水平。合成菊粉是一种完全逃避糖消化的膳食成分。在 HF 饮食中添加菊粉可以改善高甘油三酯血症和肝脂肪变性,但不能改善高胆固醇血症。本研究旨在区分合成菊粉和 3-羟基-3-甲基戊二酰辅酶 A 还原酶抑制剂(他汀类药物)的作用,这两种物质均能抑制胆固醇的生物合成。
我们检测了合成菊粉(5%)与氟伐他汀(0、4 和 8 mg/kg,口服)联合治疗对标准饮食或 HF 饮食喂养 3 周的大鼠体重、附睾白色脂肪组织重量、血清和肝脂质谱以及肝细胞色素 P450(CYP)mRNA 和蛋白谱的影响。
用 5%的合成菊粉或氟伐他汀(4mg/kg,HF 饮食喂养大鼠的致死剂量为 8mg/kg)治疗可改善 HF 饮食喂养大鼠肝三酰甘油和总胆固醇水平的升高。虽然与单独治疗相比,菊粉(5%)与氟伐他汀(4mg/kg)联合治疗更倾向于强烈抑制血清极低密度脂蛋白三酰甘油水平的升高,但在降低肝脂质水平方面没有发现相加或协同作用。HF 饮食喂养大鼠肝 CYP1A1/2 和 CYP2E1mRNA 和蛋白水平以及甲氧基 RESO 脱甲基酶和乙氧基 RESO 脱乙基酶活性降低。与氟伐他汀相比,合成菊粉更能减轻 HF 饮食喂养大鼠肝 CYP1A1/2 和 CYP2E1mRNA 和蛋白水平的降低,且联合治疗无协同作用。此外,HF 饮食喂养大鼠肝芳烃受体 mRNA 水平降低,菊粉饮食摄入可恢复至接近正常水平,与 CYP1A1/2 的变化相关。
单独饮食菊粉可有效预防肝脂肪变性的发生,改善营养状况,减轻 CYP1A1/2 和 CYP2E1 的肝表达变化,而他汀类药物联合治疗无相加或协同作用,且他汀类药物可能在 HF 饮食喂养大鼠中产生不良反应。